Newly diagnosed, previously untreated patients with metastatic pancreatic cancer
A Phase 1a/b Dose Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy (NCI# NCT04068896)
Newly diagnosed, previously untreated patients with localized pancreatic cancer who are candidates for surgical resection
Non-interventional studies, correlative and biomarker studies
A Pilot Study of Caregiver Adjustment and Quality of Life among Pancreatic Cancer Patients
Patients with previously treated metastatic pancreatic cancer
Fox Chase has a robust phase I clinical trials program with a number of trials open for those who have been previously treated for metastatic pancreatic cancer. You can search for open phase I clinical trials for pancreatic cancer here.